Future breast cancer care: ESMO Breast Cancer 2024
Transcript: Communicating diarrhoea risk
Professor Rupert Bartsch
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Well, if we are discussing now specifically neratinib, it's important to discuss with the patients the potential side effects of treatment. I always starts it before at lower doses and do a dose escalation strategy. I tell the patients if diarrhoea comes up, they should use loperamide on demand. So they receive a prescription for loperamide. And once the diarrhoea continues, well then, of course, I would interrupt Neratinib treatment. Patient would come and see me and we would reduce by one dose level, again. And then usually, it works out well.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed independently by EPG Health, which received educational funding from Pierre Fabre Medicament awarded to EPG Health to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.